107 related articles for article (PubMed ID: 17006831)
1. [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors].
Kołomecki K; Maciaszczyk P; Stepień H; Cywiński J; Cielecka J; Stepień T; Kuzdak K
Endokrynol Pol; 2006; 57(4):320-5. PubMed ID: 17006831
[TBL] [Abstract][Full Text] [Related]
2. P53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors.
Kolomecki K; Maciaszczyk P; Stepien H; Stepien T; Kuzdak K; Ulanska J
Bratisl Lek Listy; 2005; 106(10):297-300. PubMed ID: 16541608
[TBL] [Abstract][Full Text] [Related]
3. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of apoptosis-related markers (sFasL, TNF-a, p53 and bcl-2) in COPD patients.
Kosacka M; Porębska I; Korzeniewska A; Rubinsztajn R; Grabicki M; Jankowska R; Batura-Gabryel H; Chazan R
Pneumonol Alergol Pol; 2016; 84(1):11-5. PubMed ID: 26687668
[TBL] [Abstract][Full Text] [Related]
5. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
Chia SY; Milas M; Reddy SK; Siperstein A; Skugor M; Brainard J; Gupta MK
J Clin Endocrinol Metab; 2007 Feb; 92(2):468-75. PubMed ID: 17118994
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil gelatinase-associated lipocalin (NGAL) immunohistochemical expression in follicular cell-derived thyroid tumors: a novel diagnostic tool?
Barresi V; Leni A; Tuccari G; Barresi G
Histol Histopathol; 2012 Mar; 27(3):329-36. PubMed ID: 22237710
[TBL] [Abstract][Full Text] [Related]
7. Correlation of thyroid fine-needle aspiration with final histopathology: a case series.
Gürkan Dumlu E; Kiyak G; Bozkurt B; Tokaç M; Polat B; Cakir B; Güler G; Kiliç M
Minerva Chir; 2013 Apr; 68(2):191-7. PubMed ID: 23612233
[TBL] [Abstract][Full Text] [Related]
8. Analysis of P53 and P21WAF1 proteins expression in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
Pol J Pathol; 2004; 55(4):133-41. PubMed ID: 15757200
[TBL] [Abstract][Full Text] [Related]
9. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.
Owonikoko TK; Hossain MS; Bhimani C; Chen Z; Kim S; Ramalingam SS; Sun SY; Shin DM; Waller EK; Khuri FR
Cancer; 2013 Apr; 119(8):1503-11. PubMed ID: 23340930
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid.
Besic N; Sesek M; Peric B; Zgajnar J; Hocevar M
Med Sci Monit; 2008 Sep; 14(9):CR459-67. PubMed ID: 18758416
[TBL] [Abstract][Full Text] [Related]
12. Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?
Giorgadze T; Rossi ED; Fadda G; Gupta PK; Livolsi VA; Baloch Z
Diagn Cytopathol; 2004 Nov; 31(5):307-12. PubMed ID: 15468114
[TBL] [Abstract][Full Text] [Related]
13. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
14. Management of follicular and Hürthle cell neoplasms of the thyroid gland.
McHenry CR; Sandoval BA
Surg Oncol Clin N Am; 1998 Oct; 7(4):893-910. PubMed ID: 9735140
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors].
Hedayati M; Kołomecki K; Pasieka Z; Korzeniowska M; Kuzdak K
Endokrynol Pol; 2005; 56(3):252-8. PubMed ID: 16350718
[TBL] [Abstract][Full Text] [Related]
16. Determination-of apoptosis and cell cycle modulators (p16, p21, p27, p53, BCL-2, Bax, BCL-xL, and cyclin D1) in thyroid follicular carcinoma, follicular adenoma, and adenomatous nodules via a tissue microarray method.
Temiz P; Akkaş G; Neşe N; Uğur Duman F; Karakaş C; Erhan Y
Turk J Med Sci; 2015; 45(4):865-71. PubMed ID: 26422859
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients.
Niedźwiecki S; Stepień T; Kuzdak K; Stepień H; Krupiński R; Seehofer D; Rayes N; Ulrich F
Langenbecks Arch Surg; 2008 May; 393(3):275-80. PubMed ID: 18064485
[TBL] [Abstract][Full Text] [Related]
18. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid.
Suh I; Vriens MR; Guerrero MA; Griffin A; Shen WT; Duh QY; Clark OH; Kebebew E
Am J Surg; 2010 Jul; 200(1):41-6. PubMed ID: 20637335
[TBL] [Abstract][Full Text] [Related]
19. Hyalinizing trabecular carcinoma of the thyroid gland.
Gowrishankar S; Pai SA; Carney JA
Histopathology; 2008 Mar; 52(4):529-31. PubMed ID: 18315612
[No Abstract] [Full Text] [Related]
20. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma.
Haghpanah V; Shooshtarizadeh P; Heshmat R; Larijani B; Tavangar SM
Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):422-5. PubMed ID: 17122639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
